Etrolizumab in UC: Etrolizumab/placebo for patients who are refractory/intolerant to TNF inhibitors


Details of Research

Contact: Shelley Mikolainis, Research Coordinator
416-586-4800 ext 4989

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Expectation: Cohort 1: completed, Cohort 2: drug/placebo 4:1 ratio for 14 weeks, following week 14 is the Maintenance phase for those who are responders, they will receive either drug/placebo, open label extension possible for non-responders


Exclusions: strictures, prior tx with anti-integrin agents (vedolizumab)